What is BIORCHESTRA?
Headquartered in Daejeon, South Korea, and Cambridge, Massachusetts, BIORCHESTRA is fundamentally altering the therapeutic paradigm for neurodegenerative diseases. Unlike traditional pharmaceutical approaches that often target single pathological proteins—such as amyloid-beta or tau—at a late stage in disease progression, BIORCHESTRA utilizes its proprietary BMD platform to control microRNAs that regulate multiple messenger RNAs. This upstream regulatory approach, facilitated by anti-sense oligonucleotides, seeks to reverse epigenetic changes associated with cognitive impairment and synaptic loss. Furthermore, the company has developed a proprietary drug delivery system (BDDS) that enables the effective delivery of therapeutics via intravenous injection, demonstrating significant knock-down efficacy in both the cortex and deep brain structures, including the hippocampus and spinal cord.
How much funding has BIORCHESTRA raised?
BIORCHESTRA has raised a total of $45M across 1 funding round:
Series C
$45M
Series C (2022): $45M with participation from IMM Investment, LSK investment, Daily Partner, and SBI Investment Korea
Key Investors in BIORCHESTRA
IMM Investment
A leading alternative asset manager in Korea with a strong focus on global expansion and high-growth opportunities across diverse sectors including energy transition.
SBI Investment Korea
A veteran venture capital and private equity firm specializing in biotechnology, healthcare, and high-technology sectors with a broad investment mandate across Asia and the U.S.
Daily Partner
A French-based firm operating within the business services sector, providing strategic support and capital to emerging enterprises.
What's next for BIORCHESTRA?
With the recent influx of capital, BIORCHESTRA is well-positioned to advance its lead candidates through critical development phases. The strategic focus remains on validating the BDDS platform's efficacy in human clinical trials while expanding the reach of its RNA-based therapeutic pipeline. As the company scales its operations across its South Korean and U.S. hubs, it is expected to prioritize the commercialization of its disease-modifying agents. The firm's ability to address the root causes of neurodegeneration rather than merely managing symptoms provides a distinct competitive advantage in the high-stakes biotech market. Future growth will likely involve deepening its intellectual property portfolio and potentially exploring strategic partnerships with global pharmaceutical leaders to expedite the delivery of these transformative treatments to patients worldwide.
See full BIORCHESTRA company page
